STOCK TITAN
  1. Home
  2. Sec-filings
  3. IMNM
  4. [Form 4] Immunome Inc. Insider Trading Activity

Entity tied to Immunome (IMNM) director sells 100K shares

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Immunome Inc. director Isaac Barchas reported that an entity associated with him, AMBHMC II LLC, sold a total of 100,000 shares of Immunome common stock in open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 2026.

The sales occurred on July 6 and July 7, 2026, at weighted average prices of about $24.11 and $24.20 per share across specified price ranges. After these transactions, filings show 108,504 shares held indirectly and 103,259 shares held directly. Barchas disclaims beneficial ownership of the LLC-held shares beyond any pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Barchas Isaac
Role null
Sold 100,000 shs ($2.41M)
Type Security Shares Price Value
Sale Common Stock 16,906 $24.20 $409K
Sale Common Stock 83,094 $24.11 $2.00M
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 108,504 shares (Indirect, See footnote); Common Stock — 103,259 shares (Direct, null)
Footnotes (1)
  1. The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026. The weighted average sale price for the transaction report was $24.11, and the range of prices were between $24.00 and $24.29, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares. The weighted average sale price for the transaction report was $24.20, and the range of prices were between $24.00 and $24.58, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Total shares sold 100,000 shares Open-market sales reported in Form 4
Sale on July 6, 2026 83,094 shares at $24.11 weighted average AMBHMC II LLC open-market sale
Sale on July 7, 2026 16,906 shares at $24.20 weighted average AMBHMC II LLC open-market sale
Indirect holdings after transactions 108,504 shares Shares reported as held indirectly post-sale
Direct holdings after transactions 103,259 shares Shares reported as held directly on July 6, 2026
Rule 10b5-1 trading plan regulatory
"The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The weighted average sale price for the transaction report was $24.11"
beneficial ownership regulatory
"The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of his pecuniary interest in such shares, if any"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider activity did Immunome (IMNM) report in this Form 4?
Immunome reported that an entity associated with director Isaac Barchas, AMBHMC II LLC, sold 100,000 shares of common stock in open-market transactions. The trades were executed under a Rule 10b5-1 trading plan and spanned July 6 and July 7, 2026, at prices around $24 per share.

How many Immunome (IMNM) shares were sold and at what prices?
AMBHMC II LLC sold 100,000 Immunome common shares in total. One block of 83,094 shares had a weighted average price of $24.11, and another block of 16,906 shares had a weighted average price of $24.20, within disclosed intraday price ranges around those levels.

Was the Immunome (IMNM) insider sale made under a Rule 10b5-1 plan?
Yes. The filing states the reported sales occurred automatically under a Rule 10b5-1 trading plan adopted by AMBHMC II LLC on March 31, 2026. Such plans pre-schedule trades, indicating the timing of these July 2026 sales was established in advance rather than decided spontaneously.

Who actually owns the Immunome (IMNM) shares involved in the reported sale?
The filing explains that AMBHMC II LLC owns the Immunome common stock sold, while director Isaac Barchas is a managing member with power of attorney. Barchas disclaims beneficial ownership of those shares except to the extent of his pecuniary interest, if any, in the LLC-held position.

How many Immunome (IMNM) shares does the insider report holding after the sale?
After the reported transactions, filings show 108,504 Immunome shares held indirectly and 103,259 shares held directly. These figures indicate that, despite the 100,000-share sale by AMBHMC II LLC, a substantial combined position in Immunome common stock remains associated with the reporting person.

What price ranges did the Immunome (IMNM) insider sales cover?
For the 83,094-share sale, the weighted average price was $24.11 within a $24.00 to $24.29 range. For the 16,906-share sale, the weighted average price was $24.20 within a $24.00 to $24.58 range. Detailed execution prices are available on request to the issuer or SEC staff.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Barchas Isaac
(Last)(First)(Middle)
C/O IMMUNOME, INC.
18702 N. CREEK PARKWAY, SUITE 100
(Street)
BOTHELL WASHINGTON 98011
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/06/2026S(1)83,094D$24.11(2)125,410ISee footnote(3)
Common Stock07/07/2026S(1)16,906D$24.2(4)108,504ISee footnote(3)
Common Stock103,259D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026.
2. The weighted average sale price for the transaction report was $24.11, and the range of prices were between $24.00 and $24.29, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
3. ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
4. The weighted average sale price for the transaction report was $24.20, and the range of prices were between $24.00 and $24.58, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
/s/ Sandra Stoneman, Attorney-in-Fact07/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR